Rimonabant in Diabetes: This weight-loss, anti-smoking drug targets multiple risk factors in diabetics
In this trial, individuals with type 2 diabetes were randomized to receive either 5 mg of rimonabant, 20 mg of rimonabant, or placebo. All patients were on non-insulin diabetic therapy (metformin or a sulfonylurea drug). The group taking the higher dose of rimonabant had the greatest reductions in weight and waist size. Their hemoglobin A1C levels were significantly decreased, a finding which reflects improved glucose control. They also had significantly improved HDL cholesterol and triglyceride levels, and reduced systolic blood pressure.